A Quality-reviewable training record generated at the close of a Mock-FDA-Inspection rehearsal. It documents how a cohort performed against the standard — for qualification and readiness planning.
Demonstration sample · illustrative contentContext of use (CSA): This is a rehearsal debrief — a coaching record of how a cohort decided in a simulated exercise against ideal answers. It is not a gap assessment or audit of any facility, it does not write to or constitute a GxP record, and it is not a 21 CFR 211.25 training/qualification record — do not file it as one; your own QMS owns any qualification decision. Not legal or regulatory advice. PharmTech.AI is an independent service of Aligned Executive Solutions, Inc. and is not affiliated with, endorsed by, or sponsored by the U.S. FDA.
The cohort scored a composite readiness index of 78 across five inspection themes — a coaching indicator of how their decisions tracked the ideal answer. It carries no release, disposition, or qualification meaning and is not a finding about any site. Strongest: data-integrity audit-trail review. Most repetition needed: dissolution OOS investigation discipline and CAPA effectiveness verification.
Composite of 5 weighted themes · 6 participants · 1 facilitated session
"Show me how you review audit trails for the HPLC supporting release of this ER lot — who reviews, on what frequency, and how an aborted run is reconciled."
Named the second-person review at result approval and produced the audit-trail review SOP; hesitated on the cadence of independent audit-trail review for aborted/repeat runs and on who holds the reviewer role when the analyst is the supervisor.
Audit-trail review is risk-based and routine (at minimum at result approval), independent of the performer, with aborted/repeat injections reconciled against a documented justification and trended. Reviewer authority is defined and segregated from the analyst.
Investigators pull the audit trail before the printout. The fastest credibility loss is an aborted run with no contemporaneous reason — and a reviewer who reports to the performer. Cadence and independence are what they probe.
"This deviation recurred eight months after you closed the CAPA. Walk me through how effectiveness was verified before closure."
Described the CAPA actions and closure approval, but defined "effective" as actions completed rather than a pre-defined effectiveness check with a locked acceptance criterion and denominator over a defined monitoring window.
Effectiveness is verified against an acceptance criterion set before closure (e.g., zero recurrence across N defined opportunities over a defined period), with the denominator locked and the check owned by a named role — not "actions done."
"Completed" is the single most common CAPA finding. A recurrence after a "closed" CAPA with no pre-set effectiveness check reads to an investigator as a quality system that doesn't learn.
"A 12-hour ER dissolution point fails. Take me from the OOS result to the disposition decision."
Initiated a lab investigation and discussed retest, but moved toward retest/resample before a documented, science-based assignable cause and did not clearly gate hypothesis testing behind a Phase I lab assessment.
No invalidation or retest without a documented assignable cause. Phase I lab investigation first; only a confirmed lab error justifies retest; absent that, the result stands and the batch investigation (Phase II) governs disposition.
"Testing into compliance" is the OOS finding investigators are trained to hunt. The discipline is the sequence — cause before retest — and the paper that proves it.
"How is your blend-uniformity sampling plan justified, and how does it connect to content uniformity at compression?"
Produced the sampling plan and statistical basis and connected blend to in-process stratified sampling well; was less crisp on what triggers re-evaluation of the plan after a formulation or equipment change.
Sampling is statistically justified, representative of the blend, and tied to stratified in-process checks at compression; the plan is re-evaluated on a defined change trigger (formulation, equipment, scale) under change control.
Uniformity is where ER products live or die. Investigators test whether sampling is representative and whether the plan survives a change — not just whether it exists on paper.
"Justify the cleaning limit for your hardest-to-clean active on this shared line."
Defended the worst-case product bracketing and recovery studies; relied on a legacy dose-based limit rather than leading with a health-based exposure limit (PDE) for the shared-facility justification.
Limits derived from health-based exposure limits (PDE), worst-case product/most-difficult-to-clean bracketing, validated recovery, and a defensible visually-clean + analytical rationale tied to the shared-facility risk assessment.
On a shared line the PDE basis is the modern expectation. A legacy 1/1000th-dose answer invites the follow-up question you don't want.
How each participant decided per theme in this rehearsal — a coaching record, not a 21 CFR 211.25 training/qualification record. Participants are de-identified by role in this sample; the live record carries the trainee identifier your training system expects, exportable for your LMS to record as it sees fit.
| Participant (role) | Data integrity | CAPA | Dissolution OOS | Uniformity | Cleaning val. | Completed |
|---|---|---|---|---|---|---|
| A — QA Manager | Demonstrated | Practice | Demonstrated | Demonstrated | Demonstrated | 2026-06-23 |
| B — Production Supervisor | Demonstrated | Practice | Practice | Demonstrated | Demonstrated | 2026-06-23 |
| C — QC Lab Lead | Demonstrated | Demonstrated | Practice | Demonstrated | Demonstrated | 2026-06-23 |
| D — Validation Lead | Demonstrated | Practice | Demonstrated | Practice | Demonstrated | 2026-06-23 |
| E — QA Specialist | Demonstrated | Demonstrated | Practice | Demonstrated | Practice | 2026-06-23 |
| F — Process Engineer | Practice | Practice | Demonstrated | Demonstrated | Demonstrated | 2026-06-23 |
"Practice" = recommended for another rep; not a deficiency finding. Competency is against the rehearsal's ideal answers, not a site assessment.
| Focus for the next rehearsal | Theme | Suggested cadence |
|---|---|---|
| CAPA effectiveness defined before closure (acceptance criterion + locked denominator) | CAPA | Before next QRB |
| OOS sequence drill — assignable cause before any retest | Dissolution OOS | Within 30 days |
| Audit-trail review cadence & reviewer independence for aborted runs | Data integrity | Within 30 days |
| Reference | Applies to | Content version | SME review |
|---|---|---|---|
| 21 CFR 211.68(b), 211.194(a) | Data integrity / audit trail | v1.0 | SME-reviewed · 2026-06-20 |
| 21 CFR 211.192, 211.100(a); ICH Q10 | CAPA effectiveness | v1.0 | SME-reviewed · 2026-06-20 |
| 21 CFR 211.192, 211.165(a); USP <711> | Dissolution OOS | lib v0.3 | pending SME sign-off* |
| 21 CFR 211.110(a); USP <905> | Blend / content uniformity | lib v0.3 | pending SME sign-off* |
| 21 CFR 211.67, 211.182; HBEL/PDE | Cleaning validation | lib v0.3 | pending SME sign-off* |
The first two rows are shown in the SME-reviewed state as a worked example; the remainder are marked pending. In production every citation and model answer is SME-reviewed, version-controlled, and date-stamped to the current regulation before release — governed like a controlled document. Remaining content in this sample is illustrative and pending sign-off.
Evidence Pack EP-SAMPLE-001 · template v0.3 · generated 2026-06-23 · retain per your training-record policy
Get The Warning Letter Brief free every week — or talk to the operator about a Decision Simulation pilot for your team.
Get the free Warning Letter Brief Request a pilot →Demonstration sample. Illustrative content for evaluation; not a record of any real exercise or facility. Citations are shown for structure and are pending SME sign-off in this sample.
PharmTech.AI is an independent service of Aligned Executive Solutions, Inc. and is not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration. This Evidence Pack is a training and rehearsal record; it is not a gap assessment, audit, legal or regulatory advice, and does not write to or constitute a GxP record. © 2026 Aligned Executive Solutions, Inc. · PharmTech.AI · info@pharmtech.ai